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Abstract
Fv1 is the prototypic restriction factor that protects against infection by the murine leukemia virus (MLV). It was first
identified in cells that were derived from laboratory mice and was found to be homologous to the gag gene of an
endogenous retrovirus (ERV). To understand the evolution of the host restriction gene from its retroviral origins, Fv1s from
wild mice were isolated and characterized. Most of these possess intact open reading frames but not all restricted N-, B-, NR-
or NB-tropic MLVs, suggesting that other viruses could have played a role in the selection of the gene. The Fv1s from Mus
spretus and Mus caroli were found to restrict equine infectious anemia virus (EIAV) and feline foamy virus (FFV) respectively,
indicating that Fv1 could have a broader target range than previously thought, including activity against lentiviruses and
spumaviruses. Analyses of the Fv1 sequences revealed a number of residues in the C-terminal region that had evolved under
positive selection. Four of these selected residues were found to be involved in the novel restriction by mapping studies.
These results strengthen the similarities between the two capsid binding restriction factors, Fv1 and TRIM5a, which support
the hypothesis that Fv1 defended mice against waves of retroviral infection possibly including non-MLVs as well as MLVs.
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Introduction
Viruses co-evolve with their hosts, upon which they are
completely dependent for replication. As the host acquires
strategies to restrict virus infection the invaders develop counter
measures to evade restriction. The ensuing genetic conflict can
play out over an extensive timeframe [1,2,3,4]. Due to the unique
replication strategy employed by retroviruses where integration of
viral genetic information into the host genome occurs [5], the
conflict between virus and host can take an interesting twist. When
integration occurs in germ or embryonic cells, the virus can
become an endogenous retrovirus (ERV) and inherited through
the germ line [6,7]. As a result, viral gene products can be
conscripted to serve as defensive forces against further viral
infection [8]. The murine retrovirus restriction gene, Fv1, provides
perhaps the prototypic example of one such gene [9].
Fv1 restriction was first described in the early 1970s [10,11] as
an activity protecting mice against infection with murine leukemia
virus (MLV). Two semi-dominant alleles were identified, Fv1n and
Fv1b, that provide protection against B-tropic and N-tropic MLVs,
respectively [12,13]. The crucial difference between N-tropic and
B-tropic MLV maps within the viral gag gene to a single codon
encoding amino acid 110 of the mature capsid (CA) protein [14]
indicating that CA represents the target for the restriction factor.
MLVs insensitive to Fv1, called NB-tropic, carry further changes
in CA [15,16]. The mode of action of the Fv1 protein is not fully
understood but indirect evidence suggests that it binds to CA on
the cores of incoming virions shortly after virus entry into the cell
without inhibiting viral reverse transcription [17] but somehow
preventing entry of newly synthesized viral DNA into the nucleus
[9]. Based on sequence similarity, Fv1 appears to be derived from
the gag gene of an ancient ERV called MERV-L (murine
endogenous retrovirus with a leucine tRNA primer binding site)
though it appears only distantly related to MLV [18].
Amino acid 110 of CA also determines sensitivity of MLV to
another retrovirus restriction factor, TRIM5a [19], best known for
its ability to restrict HIV-1 [20]. While there is no similarity
between Fv1 and TRIM5a at the primary sequence level, both
molecules share a similar domain organization [9]. The N-
terminal domains both contain an essential coiled coil motif
involved in multimerization while the respective C-terminal
domains are required for specific virus binding [21,22]. Indeed,
the C-terminal domain of Fv1 can be replaced with CypA, a
molecule that binds HIV-1 CA, resulting in a factor that restricts
HIV-1 [23]. TRIM5 has been isolated from a number of
mammals including a variety of primates, rabbits and cows
[20,24,25,26,27]. These have been shown to restrict a range of
retroviruses from different genera. In particular, TRIM5 from the
cotton top tamarin can restrict gammaretroviruses, lentiviruses,
spumaviruses and betaretroviruses [24,28,29]. Comparison of the
target sequences show little identity and although the gammare-
troviral, betaretroviral and lentiviral CA molecules show a similar
tertiary structure [30] the spumavirus target is folded very
differently [31]. Residues in the C-terminal B30.2 domain of
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TRIM5a that determine viral recognition, and thus restriction
specificity, are under strong positive selection [32,33] and are
thought to evolve under pressure imposed by retroviral infection
[3,34,35]. However in no case have the viruses involved been
identified unambiguously [36,37,38].
In contrast, changes in Fv1 and the acquisition of its antiviral
activity are less well defined. Based on its distribution in different
subgenera ofMus, it appears that the Fv1 gene was inserted around
4–7 million years ago [39,40]. However this finding is somewhat
paradoxical because the only known target for Fv1, MLV,
probably arose considerably more recently as judged by the
distribution of its endogenous forms [41,42]. What then drove the
spread and survival of the Fv1 open reading frame? Could it be
that viruses other than MLV selected for Fv1? To address this
question we have developed a panel of Fv1 genes from different
mice and investigated their anti-viral activity against a variety of
retroviruses. These studies reveal an extraordinary degree of
plasticity in the Fv1 gene as well as two non-MLV viral targets
suggesting that a number of different viruses have moulded its
evolution.
Results
Isolation of Fv1 from wild mice
To study the evolution of Fv1, we set out to clone the gene from
a variety of species of Mus. Consistent with previous reports
[39,40], it proved possible to clone Fv1 from multiple species of the
subgenus Mus as well as single examples of the subgenera Mus
nannomys and Mus pyromys (Table 1). However, we failed to amplify
Fv1 from Mus coelomys, Apodemus and Rattus despite multiple
attempts [43], suggesting that the insertion leading to Fv1 arose
about five million years ago, at the time when the ancestors of
Pyromys, Nannomys and Coelomys diverged [44]. Sequencing revealed
open reading frames in all cases except Mus mus terricolor (dunni) and
M. m. cookii (Figure S1). In M. m terricolor, this was due to a single
base pair deletion at position 224 that causes a frameshift and
premature stop, while in M. m. cookii, a base pair transition from C
to T at position 650 coupled with a 5 base pair deletion causes the
Table 1. Sources of Fv1 clones.
Species Location DNA sourcea Abbreviation Accession number
PCR Clones Lab C57BL/J TJL Fv1b X97719
Lab AKR/J TJL Fv1n X97720
Lab DBA/2J TJL Fv1d KF975437
Lab 129/SvEv TJL Fv1nr AY294331
Lab LG/J TJL Fv1lg KF975438
M.m.molossinus Japan TJL MOL KF975439
M.m.bactrianus Iran LGP BAC KF975440
M.m.castaneous India LGP CAS1 KF975441
Thailand TJL CAS2 KF975442
M.m.spretus Spain TJL SPR1 KF975443
France LGP SPR2 KF975444
M.m.spicilegous Yugoslavia LGP SPI KF975445
M.m.caroli Thailand TJL CAR1 KF975446
Thailand TJL CAR2 KF975447
M.m.cervicolor India? JMC CER KF975448
M.m.terricolor India MDTF DUN KF975449
M.m.cooki Thailand LGP COO KF975450
M.m.famulus India JMC FAM KF975451
M.n.minutoides Africa BAM MIN1 KF975452
M.p.platythrix India LGP PLA KF975453
aLGP, a gift from Drs Francois Bonhomme and Jean-Louis Gue´net, Laboratoire Genome et Populations, Montpellier, France; JMC, a gift from Dr John Coffin, Tufts
University, Boston, USA; BAM, a gift from Dr Beverley Mock, NCI, Bethesda, USA; TJL, purchased from the Jackson Laboratory, Bar Harbor, USA; MDTF, M.dunni tail
fibroblast cells [65].
doi:10.1371/journal.ppat.1003968.t001
Author Summary
We have followed the evolution of the retroviral restriction
gene, Fv1, by functional analysis. We show that Fv1 can
recognize and restrict a wider range of retroviruses than
previously thought including examples from the gammar-
etrovirus, lentivirus and foamy virus genera. Nearly every
Fv1 tested showed a different pattern of restriction activity.
We also identify several hypervariable regions in the
coding sequence containing positively selected amino
acids that we show to be directly involved in determining
restriction specificity. Our results strengthen the analogy
between Fv1 and another capsid-binding, retrovirus
restriction factor, TRIM5a. Although they share no
sequence identity they appear to share a similar design
and appear likely to recognise different targets by a
mechanism involving multiple weak interactions between
a virus-binding domain containing several variable regions
and the surface of the viral capsid. We also describe a
pattern of constant genetic change, implying that different
species of Mus have evolved in the face of ever-changing
retroviral threats by viruses of different kinds.
Evolution of the Fv1 Gene
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formation of a premature stop codon. Interestingly, in three cases,
M. m. molossinus, M. m. spretus and M. m. caroli, 2 different sequences
were amplified in reproducible fashion. Pairs clustered together in
phylogenetic analyses, suggesting the presence of more than one
segregating allele in these subspecies of mice.
Sequence comparisons reveal that the N-terminal region of Fv1,
which encodes an extended coiled coil region necessary for
restriction activity [23,45], is well conserved (Figure S1). Com-
pared to M. m. caroli, M. m. famulus, Mus nannomys minutoides and
Mus pyromus platythrix, all the other Fv1s contained a 3 amino acid
insertion near the N-terminus (Figure S1). This change was not
important for restriction activity. By contrast, the C-terminal
domain shows significant variation in regions important for Fv1
function. Four variable regions, which we designate VA–D can be
distinguished (Figure 1). The first variable region (residues 247–
276) overlaps a sequence called the Major Homology Region
(MHR) that is present in the CA protein of all retroviruses as well
as Fv1 [18,46,47] and is essential for Fv1 function [48]. Variable
regions B–D (amino acids 345–358, 375–401 and the extreme C-
terminus) contain the residues we had previously shown to
distinguish the predicted products of the n and b alleles of Fv1.
These differences are found at amino acids 358, 399 and the very
C-terminus of the Fv1 protein where an apparent deletion of
1.3 kb in genomic DNA resulted in a nineteen amino acid length
difference [18]; together they appear responsible for the differ-
ences in restriction specificity [48]. The present analysis showed
that the more divergent mice contained the residues that are found
in Fv1n at positions 358 and 399 but they did not contain the
1.3 kb deletion. This suggested that Fv1n arose from the progenitor
Fv1, which was similar in length to Fv1b, through an internal
deletion, while Fv1b evolved through the substitution of the
residues at positions 358 and 399.
Variable regions A–C appear to arise by point mutation but
region D shows more significant changes in nucleotide sequence.
The three most distantly-diverged mice, M. n. minutoides, M. m.
famulus and M. p. platythrix each appear to have B1 repeat
sequences inserted, apparently independently, near the deletion
site that gave rise to the Fv1n allele (Figure 2). They contribute the
last few amino acids of Fv1 resulting in C-termini that are rather
different from either Fv1n or Fv1b. Other differences in this region
arise from short insertions or deletions perhaps resulting from
polymerase slippage during DNA replication. Thus the clones,
Figure 1. Features of Fv1. At the top of the figure is a schematic of the Fv1 protein showing the relative positions of the previously mapped
functional domains including coiled coil and major homology regions as well as the host range specificity regions previously defined by a comparison
of Fv1n and Fv1b [48]. Below is shown the positions of four variable regions (VA–D), the amino acid differences that define them and the number of
times each amino acid occurs. Based on a comparison of 19 mice (Table 1 plus Table 2).
doi:10.1371/journal.ppat.1003968.g001
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SPR1 and SPR2, we amplified from M. m. spretus of French and
Spanish origins differed by four amino acids; the same difference
also seen between Fv1b and CAS2 (Figure 2).
Different restriction activities of wild mice Fv1
By analogy with other restriction factors it seems likely that the
variation seen in Fv1 arose by selection and this would be reflected
in changes in restriction specificity. To test this we examined the
restriction properties of Fv1 we had cloned from different mice
(Table 1) as well as a number of genes synthesized on the basis of
published sequences (Table 2) [40,49]. A tree based on these
sequences is shown in Figure 3; it shows good agreement with the
accepted phylogeny of genus Mus [50]. The Fv1 genes were
introduced into pLgatewayIYFP and tested for restriction of
different MLVs using a two-colour FACS assay [19,51]. The
results are shown in Table 3.
As previously shown, the Fv1n gene restricted B-MLV but not
N- or NB-MLV while Fv1b, when expressed at protein levels seen
in transduced cells, restricted N- and NB- MLV and also had a
weak activity against B-MLV [51]. The Fv1 gene from M. m.
molossinus and M. m. spretus restricted both N- and B-MLV but not
NB-MLV, suggesting that they could be similar to Fv1nr [16].
Hence, we also examined three N-MLV CA variants (D82N,
H114R and L117H) that confer resistance to Fv1nr [16]. Variants
N-MLV H114R and N L117H, which we have found to be NR
tropic, were also resistant to both the Fv1MOL1 and Fv1SPR1
proteins. In contrast, N-MLV N82D was restricted by Fv1MOL1
but not by Fv1SPR1, suggesting that Fv1MOL1 is subtly different
from Fv1nr. We have cloned the Fv1nr gene from 4 different strains
of mice (129SvEv, NZB/B1NJ, NZW/LacJ and RF/J); all
contained a single nucleotide change compared to Fv1n, causing
a serine to phenylalanine substitution at residue 352. While
Fv1MOL1 also encoded phenylalanine at position 352, Fv1SPR1
possesses a serine at the corresponding position. Taken together,
these results suggest that other changes could also be involved in
determining the nr-specificity. Perhaps surprisingly, Fv1 from two
closely related species, M. m. castaneus and M. m. spicelegus lacked
perceptible Fv1 activity against MLV.
Other Fv1 genes displayed a variety of restriction phenotypes.
Fv1 from two asian members of the Mus subgenus, M. m. caroli and
Figure 2. The C-terminal region of selected Fv1 proteins. Nucleic acid and predicted amino acids found at the C-terminus of selected Fv1
genes. The twelve nucleotides shown in purple for Fv1n are found 1.3 kb downstream in Fv1b [18]. Sequences shown in blue (FAM, MIN) correspond
to nucleotides 1–27 of the consensus B1 repeat [69]. The sequences in red (PTX) might also come from a rearranged B1 repeat as they correspond to
nucleotides 30–44 and 56–65 of the consensus sequence. The nucleotide in orange corresponds to a unique point mutation found in Mus m. spretus
resulting in a novel stop codon.
doi:10.1371/journal.ppat.1003968.g002
Table 2. Sources of Fv1 synthesized clones.
Species Location
DNA
sourcea Abbreviation
Accession
number
M.m.macedonicus Bulgaria? Yan MAC FJ603564
M.n.minutoides Africa Yan MIN2 FJ603554
M.n.gratus Uganda Yan GRA FJ603556
M.n.setulosis Kenya Yan SET FJ603555
M.n.triton Uganda Yan TRI FJ603557
M.p.saxicolor India Yan SAX FJ603560
aYan, synthesized based on sequence published in [40].
doi:10.1371/journal.ppat.1003968.t002
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M. m. cervicolor, lacked Fv1 activity directed against MLV as did the
two members of the Pyromys subgenus that we tested, M. p. platythrix
and M. p. saxicolor (Table 3). By contrast two members of the
Nannomys subgenus, M. n. ninutoides and M. n setulosis were active
with the M. n. minutoides clones restricting all six MLVs tested. The
M. m. famulus sample, whose position in Mus phylogenetic trees is
relatively poorly defined, showed weak activity against N, B, and
NB-tropic MLVs. Thus more than half of the Fv1 genes with intact
open reading frames did not seem to have any activity against
MLV, the target that defines the Fv1 gene, even though they were
expressed at similar levels to restricting genes in transduced cells
(Figure S2). Further, the extent and specificity of restriction of
different MLVs varies significantly. Clearly, the properties of the
restriction gene have changed since the gene first became part of
the mouse germ line but whether MLV alone was responsible for
selecting such changes remained an open question.
Novel restriction specificities of wild mice Fv1
Prompted by the example of TRIM5a that can restrict multiple
genera of retrovirus [24,29], we decided to investigate the
hypothesis that non-MLV retroviruses might play a role in
shaping the evolution of Fv1, by testing a number of different
retroviral vectors for restriction by Fv1 from wild mice. These
included other gammaretroviruses like Gibbon Ape Leukemia
Virus (GALV), Feline leukemia Virus (FeLV) and Porcine
Endogenous Retrovirus-A (PERV-A), lentiviruses such as HIV-1,
HIV-2, SIVmac, Equine Infectious Anemia Virus (EIAV) and
Feline immunodeficiency Virus (FIV), as well as foamy viruses
including Prototypic Foamy Virus (PFV), Simian Foamy Virus
(SFV) and Feline Foamy Virus (FFV). Some of these results are
presented in Table 4. The data show that Fv1 from M. m. caroli,
that lacked activity against MLV, restricted FFV strongly and PFV
weakly. Moreover, Fv1 from M. m. spretus, which restricted N- and
B-MLV, and from M. m. macedonicus, which inhibited N-MLV,
were also active against the lentivirus EIAV. By contrast GALV,
FeLV, PERV-A, SFV, HIV-1, SIVmac and FIV were not
restricted by any of the Fv1 genes in the panel (Table 4 and data
not shown). Formally it remains possible that the novel specificities
observed result from over expression. Unfortunately, no cell lines
expressing Fv1CAR1 and Fv1SPR1 at endogenous levels are
available, precluding a direct test of this idea. However we are not
aware of any examples of complete restriction of novel viruses
resulting from such a mechanism.
To further characterize restriction mediated by Fv1CAR1 and
Fv1SPR1 stable cell lines were derived by transducing MDTF cells
with retroviral vectors carrying these genes and selecting for G418-
resistant single cell clones. These cell lines were used in virus
titrations by measuring the percentage of transduced cells by
FACS with different amounts of virus (Figure 4A,B). As expected,
the titre of EIAV was dramatically reduced in the cell line
expressing Fv1SPR1 compared to the untransduced MDTF
control (Figure 4A). Similarly titres of FFV and PFV were greatly
reduced in MDTF cells expressing Fv1CAR1 compared to
untransduced while titres of SFV were unaffected by the presence
of the Fv1 gene (Figure 4B). These results confirm the observations
made with the 2 colour FACS assay that Fv1 from some wild mice
can restrict non-MLV retroviruses.
Fv1 is thought to interfere with MLV replication by preventing
nuclear import of newly synthesized viral DNA [9]. To test
whether this was also true for EIAV and FFV, we examined the
Figure 3. Phylogenetic tree of Fv1 sequences. The tree was generated from the open reading frames listed in Tables 1 and 2 (bases 1 to 1278 in
Fv1b) using the MegAlign programme from the DNASTAR Lasergene package. The highly divergent C-terminus was excluded from the analysis and
the aspartic acid residue at position 426 (Fv1b numbering), which was the last residue conserved in all the sequences, was chosen as the cut-off point.
The number of substitution events is shown at the bottom of the tree while the distances between sequence pairs is represented by the length of the
branch pairs. The distance values were calculated using the Kimura distance formula that takes into account the number of non-gap mismatches and
silent substitutions.
doi:10.1371/journal.ppat.1003968.g003
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fate of viral DNA in restricting cell lines. Testing EIAV replication
in Fv1SPR1 cells shows no inhibition of reverse transcription as
measured by levels of newly synthesized late DNA products
(Figure 4C). However levels of 2-LTR circles, which are thought to
form only after nuclear entry [52], are substantially reduced
suggesting a block in nuclear uptake. In Fv1CAR1 cells a reduction
in FFV 2-LTR circles, with no change in late RT products, was
also observed (Figure 4D), again consistent with a block in nuclear
import. However, interpretation of these data is complicated by
the fact that the majority of FFV DNA synthesis is thought to
occur in the producer cells [53]. Nevertheless, it appears likely that
Fv1 is acting to block lentivirus and foamy virus replication at the
same stage in the viral life cycle as seen with MLV.
Mapping the specificity determinants of the novel
restriction activities
To identify the specificity determinants of these novel restriction
activities, chimeric Fv1 genes were constructed and tested for
restriction. To look at FFV restriction, we made chimeras between
Fv1CAR1, which restricted only FFV, and Fv1n, which restricted B-
MLV. Schematic views of the constructs made and the
corresponding restriction data are shown in Figure 5A. Replace-
ment of a C-terminal fragment of Fv1n (from residue 318) with the
corresponding fragment from Fv1CAR1 generated a chimera
(Fv1nC4) capable of restricting FFV. Replacement with a shorter
fragment starting from residue 353 (Fv1nC5) was insufficient to
confer restriction, suggesting that the determinants of FFV
restriction were found between residues 316 and 352 of Fv1 from
M. m. caroli. In the reciprocal chimeras, replacing the small C-
terminal segment of Fv1CAR1 beginning from residue 352 with
that from Fv1n did not result in any loss of activity against FFV.
However, when a larger fragment beginning at residue 316 was
replaced, activity was lost, confirming the presence of the
determinants of FFV restriction within the region of Fv1CAR1
between residues 316 and 352. Within this region, there are 5
residues that differ between Fv1n and Fv1CAR1. These were
systematically changed to identify the residues involved in
Table 3. Restriction activity of various Fv1s against different MLVs.
Virus
Fv1 allele N-MLV B-MLV NB-MLV N-MLV D82N N-MLV H114R N-MLV L117H
Fv1b 0.09±0.01 0.4860.02 0.16±0.01 0.09±0.01 0.16±0.01 0.12±0.02
Fv1n 1.1860.07 0.11±0.01 1.1460.01 1.2060.04 1.1560.01 1.1560.04
MOL 0.20±0.03 0.22±0.02 1.0760.01 0.21±0.01 1.2460.01 1.1960.01
CAS2 1.1760.03 1.1560.01 1.1360.03 1.2460.07 1.1660.03 1.1960.01
SPI 1.1860.04 1.1860.06 1.1660.05 1.2060.01 1.1060.02 1.1660.06
SPR1 0.12±0.01 0.13±0.01 1.1760.01 0.8960.01 1.0760.02 0.6860.07
CAR1 1.2160.07 1.1560.03 1.1760.01 1.3160.02 1.2460.02 1.3160.06
CAR2 1.0260.01 1.1360.01 1.1660.03 1.2160.01 1.1460.01 1.2060.03
CER 0.9060.01 1.1560.01 1.1560.01 1.1760.02 1.2060.08 1.1660.06
FAM 0.3160.01 0.3660.02 0.3860.03 0.3760.01 0.7360.04 0.2960.01
MIN1 0.23±0.06 0.18±0.02 0.24±0.01 0.17±0.02 0.21±0.01 0.22±0.02
PLA 1.0960.05 1.0860.01 1.1760.04 1.1160.01 0.8160.01 1.1960.04
MAC 0.18±0.01 1.2460.02 1.2460.01 n.d. n.d. n.d.
MIN2 0.04±0.01 0.04±0.01 0.10±0.01 n.d. n.d. n.d.
GRA 1.2260.03 1.2060.01 1.2560.01 n.d. n.d. n.d.
SET 0.10±0.01 0.06±0.01 1.2560.02 n.d. n.d. n.d.
TRI 1.1260.01 0.4560.01 1.3160.01 n.d. n.d. n.d.
SAX 1.3260.02 1.3060.02 1.3060.03 n.d. n.d. n.d.
doi:10.1371/journal.ppat.1003968.t003
Table 4. Restriction activity of various Fv1s against different
viruses.
Virus
Fv1 allele PFV SFV FFV EIAV HIV-1
Fv1b 0.9960.02 1.1060.02 1.0060.02 0.5260.01 1.1260.01
Fv1n 1.0860.06 1.0260.01 1.0660.01 1.1760.04 1.1260.01
MOL 1.1160.07 1.0860.02 1.0460.01 1.1860.12 1.1660.05
CAS2 1.1060.07 1.0560.01 1.0660.02 1.2860.06 1.1460.01
SPI 1.0060.03 1.0560.02 1.0360.02 0.7060.06 1.1360.01
SPR1 1.0460.03 1.0560.01 1.0260.01 0.20±0.01 0.7060.01
CAR1 0.3360.01 0.9260.02 0.13±0.01 1.1760.09 1.3160.01
CAR2 1.3660.04 1.0960.01 1.1060.02 1.2860.12 1.1960.04
CER 1.0460.02 1.1360.03 1.0960.02 0.8160.02 1.1460.01
FAM 1.0560.01 1.0860.01 1.0660.01 0.9660.03 1.1660.01
MIN1 1.0260.01 1.1060.01 1.3160.02 1.4460.10 1.2160.03
PLA 1.0060.03 1.0360.02 1.0460.01 1.0860.01 1.1060.01
MAC 1.0560.03 0.9960.01 1.0160.03 0.21±0.01 0.9660.01
MIN2 1.0060.02 1.0460.01 1.0060.02 1.0860.04 1.1060.02
GRA 0.9160.01 1.0360.01 0.9660.01 0.9760.01 1.0060.01
SET 0.8160.03 1.0160.01 0.9960.01 0.9960.04 1.0960.02
TRI 0.8860.05 1.0460.02 0.9860.02 0.9660.01 1.1760.04
SAX 1.0160.02 1.0260.01 1.0560.09 0.9560.03 1.1060.01
doi:10.1371/journal.ppat.1003968.t004
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specificity determination (Figure 5B). No single change could
endow Fv1n with the ability to restrict FFV (Figure 5B). However
two single changes at positions 349 and 352 of Fv1CAR1 resulted
in loss of FFV restriction. We therefore mutated both these
positions in Fv1n to the corresponding amino acids found in
Fv1CAR1. This generated a construct (Fv1nE349KS352Y) capa-
ble of restricting FFV. Taken together, these results indicate that
both lysine 349 and tyrosine 352 in Fv1 from M. m. caroli are
crucial for FFV restriction. We had previously shown that MLV
recognition maps downstream of this region [48]; it was therefore
interesting to see that Fv1nE349KS352Y (and chimera Fv1Cn5)
could recognize both B-MLV and FFV in an additive fashion.
To examine EIAV restriction by Fv1 from M. m. spretus, a
second set of chimeras was made between Fv1SPR1, which restricts
N-MLV, B-MLV and EIAV, and Fv1n, which only restricts B-
MLV. Restriction of EIAV was seen with chimeras only when
amino acids from positions 191 and 271 were derived from
Fv1SPR1 (Fig. 6A) suggesting that the determinants of EIAV
restriction lay between these residues. Interestingly, the determi-
nants for MLV restriction were slightly different from those of
EIAV. Replacing a short segment of C-terminus of Fv1n (from
residue 366) with that from Fv1SPR1 in Fv1nS3 was sufficient to
confer restriction of N-MLV, suggesting that this region contained
determinants of N-MLV restriction. However, a reciprocal change
in Fv1SPR1 (Fv1Sn3) did not abolish N-MLV restriction. It was
only when a C-terminal segment beginning with residue 191 was
replaced from Fv1SPR1 (Fv1Sn1) that the restriction of N-MLV
was lost. This suggested that additional requirements for N-MLV
restriction were found between residues 191 and 271 of Fv1 from
M. m. spretus, perhaps overlapping with those that determined
EIAV restriction.
There are 5 differences between Fv1n and Fv1SPR1 in the
segment between residues 191 and 271 (Figure 6B). To identify the
residues involved in restriction, site-directed mutagenesis was
employed to change the residues in Fv1n to those present in
Fv1SPR1. Reciprocal mutations were also made in Fv1SPR1.
Figure 4. Staging restriction blocks in novel Fv1s. MDTF cells were transduced with Fv1CAR1 and Fv1SPR1, then stable Fv1-expressing cell lines
selected and tested for restriction of virus replication by FACS (A, B) or by PCR to measure viral DNA synthesis or formation of circular viral DNA
containing two LTRs (C, D).
doi:10.1371/journal.ppat.1003968.g004
Figure 5. Mapping the determinants of FFV restriction by Fv1 from M. m. caroli. (A) Analysis of restriction by chimeric Fv1 constructs. (B)
Analysis of restriction by site directed mutant forms of Fv1.
doi:10.1371/journal.ppat.1003968.g005
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These mutants were tested for restriction of EIAV, N- and B-
MLV. The substitution from arginine to cysteine at position 268 in
Fv1n was sufficient to confer the ability to restrict both N-MLV
and EIAV. The reciprocal change in Fv1SPR1 resulted in a partial
reduction in restriction of all three viruses. These results indicated
that residue 268 was the major determinant of EIAV restriction by
Fv1SPR1 and had an influence on MLV restriction but that other
neighbouring residues were also important. A lysine to glutamine
Figure 6. Mapping the determinants of EIAV restriction by Fv1 from M. m. spretus. (A) Analysis of restriction by chimeric Fv1 constructs. (B)
Analysis of restriction by site directed mutant forms of Fv1.
doi:10.1371/journal.ppat.1003968.g006
Figure 7. Properties of the variable regions of Fv1. Proteins corresponding to the Fv1SPR1, Fv1CAR1 and Fv1nr alleles are illustrated. Shaded
positions indicate amino acids showing positive selection [40], residues in triangles have been implicated in restriction specificity (this paper, [16,48]).
doi:10.1371/journal.ppat.1003968.g007
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change at residue 270 in Fv1n resulted in low but reproducible
restriction of EIAV and N-MLV though the reciprocal change in
Fv1SPR1 had little effect. Interestingly, substitution of the residue
at position 261 in both Fv1n and Fv1SPR1 seemed to abolish the
restriction of B-MLV, indicating that this residue was involved in
the interaction with B-MLV. We conclude that residues 261, 268
and 270 in Fv1 from M. m. spretus are all involved in virus
recognition. However, it would appear that recognition of EIAV
by Fv1 from M. m. macedonicus has arisen in a different manner as it
contains arginine rather than cysteine at position 268.
Discussion
In this study of Fv1 evolution we have demonstrated that Fv1
shows substantial sequence variation in its C-terminal half, the
region of the protein thought to contain determinants of restriction
specificity. In addition we have shown that Fv1 is capable of
restricting viruses other than its previously defined targets and
identified the sequence variation responsible for these novel
targets. We note that some Fv1 alleles do not appear to possess an
associated restriction activity; it would be of considerable interest
to determine whether they recognize other targets.
A previous study had identified six codons, specifying Fv1
amino acids 261, 265, 270, 362, 299 and 401, that show evidence
for positive selection during the course of Mus evolution [40].
These represent potential sites of interaction between Fv1 and its
target viruses. Combining these data with our previous studies of
Fv1 specificity [16,48], it seems reasonable to conclude that the
four variable regions defined in Figure 1 constitute four domains
collectively or individually involved in target selection and binding
(Figure 7). Thus VRA (amino acids 247–276) includes the
positively selected residues 261, 265 and 270 as well as three
residues, 261, 268 and 270, shown to be important for EIAV
restriction by Fv1SPR1 while VRB (amino acids 345–358) has
positively selected amino acid 352, amino acids 349 and 352
important for FFV recognition by Fv1CAR1 as well as residues
352 and 358 important for NR- and N- versus B-tropism,
respectively [16,48]. Variable region C (amino acids 375–401)
contains positively selected amino acids 399 and 401 while residue
399 was also implicated in determining N- versus B-tropism [48].
The nature of the length variation at the C-terminus precludes
computational analysis for positive selection; nevertheless func-
tional studies [48] provide compelling evidence that this region
can also alter restriction specificity.
We have previously noted that CA binding restriction factors
Fv1 and TRIM5a share certain design features despite lack of
sequence similarity [9]; the present study strengthens this analogy.
Both factors possess an N-terminal coiled-coil region allowing
dimer formation. They also contain other sequences facilitating
the formation of higher order multimers. Both contain a C-
terminal domain responsible for virus binding that can be
substituted with the cellular CA binding cyclophilin A protein to
give a fusion protein capable of restricting HIV-1 and other
lentiviruses [23,54]. We now provide evidence that the CA
binding domain of Fv1, like TRIM5a [24,32,55,56], appears to
comprise multiple variable regions, showing attributes of positive
selection, implying virus driven evolution [3]. Further, Fv1 is
capable of recognizing multiple genera of retrovirus. It seems
possible that the ability to recognize multiple viruses by low affinity
binding with avid binding provided by multimerisation [57]
Figure 8. Events in the evolution of the Fv1 gene. A phylogenetic tree showing the approximate times of Fv1 acquisition and hypothetical virus
infections leading to selection of new retroviral restriction activities. Colored mice indicate Fv1 activity against at least one virus.
doi:10.1371/journal.ppat.1003968.g008
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represents a common theme in restriction factor design. Further
insights into the interaction between virus and restriction factor
requires detailed structural information; unfortunately both Fv1
and TRIM5a are relatively recalcitrant to such studies.
The origin of Fv1 remains unclear. It is only present in Mus and
appears related to the gag gene of the endogenous retrovirus family
ERV-L [18,47]. This suggests that Fv1 might be derived from an
endogenous retrovirus following the loss of both LTRs and pol coding
sequences [58]. Interestingly a significant increase in MERV-L copy
number took place at around the time of the separation of Mus
subgenera [59], the time when Fv1 became part of theMus germline.
However sequence alignments indicate that Fv1 andMERV-L share
only 43% amino acid identity whereas the different genomic
MERV-L elements are much more closely related to one another
(,5% nucleic acid divergence). BLAST searches of the NCBI non-
redundant genome databases reveal no sequences intermediate
between Fv1 and MERV-L. This suggests that Fv1 might be derived
from an exogenous virus related to ERV-L that has not made its
home as an intact ERV, at least not in any species so far sequenced,
and may no longer exist in infectious form. As such Fv1might be the
last remnant of an ancient extinct virus, or paleovirus [2].
Unfortunately this inability to identify the proximal precursor for
Fv1 prevents us from determining whether or not the original
transgene showed restriction activity and, if so, against which virus.
The selection and continuing existence of the Fv1 open reading
frame implies that it provides an evolutionary advantage,
presumably by providing protection against retroviral infection.
The observation of multiple restriction specificities suggests that a
variety of unknown viruses have contributed to this process. Taken
together with frequent genetic changes to inactivate [60] or block
MLV receptors [61], these data imply that multiple virus
epidemics have occurred in the course of mouse evolution [62].
One might postulate that at least four significant virus exposures
have occurred during Mus evolution (Figure 8). One took place
after the divergence of Nannomys; a second occurred in M. m. caroli;
a third in mice in countries surrounding the Mediterranean Sea
and a fourth in the Mus musculus subfamily. In turn this prompts
the question of how the current properties of a restriction factor
reflect the properties of the viruses involved in selection, a question
that is as relevant for TRIM5a as for Fv1. Specifically one might
ask whether the ability to restrict one genus of retrovirus reflects
prior exposure to that kind of virus. An affirmative answer might
resolve the vexed question of whether foamy viruses have
deleterious effects on their hosts [63], possibly as co-pathogens
[64] since both Fv1 (this paper) and TRIM5a [29] have evolved to
see one or more such virus. Alternatively, changes selected by, say,
a gammaretrovirus like MLV, might fortuitously result in
recognition of a lentivirus like EIAV or a foamy virus like FFV.
In light of the shorter generation time of mice compared to
primates Fv1 could provide a more useful system for studying
evolution of restriction specificity than does TRIM5a. The
observation of multiple alleles of Fv1 might also suggest that
selection is an ongoing process offering opportunities for
experimental analysis. In particular, the evolution of restriction
activity against the lentivirus EIAV, which appears to have
happened in two different ways in M. m. spretus and M. m.
macedonicus as well as the kind and source(s) of the virus(es) involved
would appear worthy of more detailed investigation.
Materials and Methods
Fv1 cloning
Genomic DNA samples for Mus musculus laboratory mouse
strains C57BL/6J, AKR/J, DBA/2J, 129/SvEv, and LG/J, M. m.
spretus (M. spretus), M. m. caroli (Mus caroli), M. m. molissinus
(MOLD/Rk) and M. m. castaneous were purchased from the
Jackson Laboratory. Genomic DNA from M. p. platythrix, M. m.
cookii, M. m. spicilegus, M. m. spretus, M. m. castaneous and M. m.
bactrianus were gifts from Dr. F. Bonhomme (Laboratoire Genome
et Populations, Universite de Montpellier II, CNRS). M. n.
minutoides genomic DNA was a gift from Dr. B. Mock (National
Cancer Institute, NIH), while M. m. famulus and M. m. cervicolor
genomic DNA were gifts from Dr. John Coffin (Tufts University
School of Medicine, Boston). M. m. terricolor (dunni) genomic DNA
was prepared from a Mus dunni tail fibroblast (MDTF) line [65]
using the DNeasy blood and tissue kit (Qiagen). The Fv1 ORF was
PCR amplified from mouse genomic DNA using primers PL80
and GT17 (see Table S1 for primer sequences) that permit the
amplification of a sequence starting from 3056 bp upstream of the
start codon of Fv1 to 2684 bp downstream of the start codon.
Sequence analysis of this region from in-bred mice identified 2
SacI sites downstream of the PL80 primer-binding site, while
GT17 contained a SalI site. The PCR products were hence cloned
initially as SacI/SalI fragments into M13 phage and sequenced.
Subsequent subcloning of Fv1 ORFs was carried out following
amplification with the primers GatewayFv1F and Gateway
Fv1rev. The PCR product was used in a second amplification
reaction with primers UniversalF and UniversalRev to attach the
attB sites to the ends of the fragment. This was then inserted into
pDNR221, which is an entry vector to the Gateway Cloning
system, using BP clonase (Invitrogen). Finally, the entry clone was
used in a LR reaction with LR clonase to insert the Fv1 ORF into
either pLgatewayIRESEYFP or pLgatewaySN to generate retro-
viral delivery vectors carrying either the EYFP or G418 resistance
marker. Details of these different clones as well as the abbrevi-
ations used for their designation are summarized in Table 1.
Fv1 open reading frames from M. m. macedonicus, M. n. minutoides,
M. n. gratus, M. n. setulosis, M. n. triton and M. p. saxicolor were
synthesized chemically (GENEART, Life Technologies) based on
their published sequences [40] with added attB sites and
introduced into pLgatewayIRESEYFP via pDNR221. These
clones are also summarized in Table 2.
Construction of chimeric Fv1s
Fv1 chimeras were generated by overlapping PCR. Briefly, a 59
fragment was amplified from one parental sequence while a 39
fragment was amplified from the other. The two fragments were
then combined in a third amplification reaction using forward and
reverse primers that annealed to the 59 and 39 ends of Fv1
respectively. Internal primer pairs were designed to target regions
of identity between the two parental sequences. The sequences of
the primers are shown in Table S1.
To generate the Fv1nC series, the 59 fragments were amplified
from Fv1n using TopoFv1F and either C1Rev, C3Rev, C4Rev or
C5Rev, while the 39 fragments were amplified from Fv1caroli
(CAR1) using either C1F, C3F, C4F or C5F and Fv1caroliRev.
The 2 fragments were joined in a reaction using TopoFv1F and
Fv1caroliRev to yield Fv1nC1, Fv1nC3, Fv1nC4 and Fv1nC5.
Similarly, the 59 fragments for the reciprocal series Fv1Cn were
amplified from Fv1caroli (CAR1), using the same primer pairs as the
Fv1nC series, while the 39 fragments were amplified from Fv1n
using either C1F, C3F, C4F or C5F and Fv1nRev. These
fragments were joined using primer pair TopoFv1F and Fv1nRev,
yielding Fv1Cn1, Fv1Cn3, Fv1Cn4 and Fv1Cn5.
The 59 fragments for the Fv1nS series were amplified from Fv1n
using TopoFv1F and either S1Rev, S2Rev or S3Rev, while the 39
fragments were amplified from Fv1spretus (SPR1) using either S1F,
S2F or S3F and Fv1spretusRev. The 2 fragments were joined
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together in a reaction using TopoFv1F and Fv1spretusRev to yield
Fv1nS 1, Fv1nS2 and Fv1nS3. Similarly, the 59 fragments for the
reciprocal series Fv1Sn were amplified from Fv1spretus (SPR1),
using the same primer pairs as the Fv1nS series, while the 39
fragments were amplified from Fv1n using either S1F, S2F or S3F
and Fv1nRev. These fragments were joined using primer pair
TopoFv1F and Fv1nRev, yielding Fv1Sn1, Fv1Sn2 and Fv1Sn3.
The chimeric fragments were cloned into pENTR/D-TOPO
(Invitrogen) and verified by sequencing before transferring into the
retroviral vector pLgatewayIRESEYFP.
Site directed mutagenesis
The point mutants were generated by site directed mutagenesis
using the primer pairs listed in Table S1. Mutagenesis was carried
out in 50 microlitre reactions containing 2.5 units of Pfu ultra,
10 ng of template, 0.2 mM dNTP and 125 ng each of the forward
and reverse primer. The reaction was performed in a thermal
cycler at 95uC for 2 minutes followed by 18 cycles of 95uC for
30 seconds, 55uC for 1 minute and 68uC for 9 minutes 30 sec-
onds. The PCR product was then digested with10 units of DpnI
(Roche) for 1 hour before transforming XL10Gold cells (Agilent
technologies). Colonies were screened by restriction digest and the
mutations were verified by sequencing.
Cells and virus production
MDTF and 293T cells were maintained in DMEM containing
10% foetal calf serum and 1% penicillin and streptomycin. Viruses
were made by the transient transfection of 293T cells as previously
described [19,51]. Delivery viruses were produced by co-
transfecting pcz-VSVG, pHIT60 and a retroviral vector contain-
ing Fv1 and either the EYFP or G418 resistance gene. N-, B- and
NB-tropic MLV tester viruses were generated by co-transfection of
pczVSVG, pczCFG2fEFPf and either pCIGN, pCIGB or pHIT60
respectively, while the NR-tropic viruses were made using a
mutagenized form of pCIGN as previously described [16]. EIAV
tester viruses were made using pczVSVG, pONY3.1 and
pONY8.4ZCG or pONY4.1Z [66], while PFV, SFV and FFV
were produced with pciSFV-1envwt and either pczDWP001,
pcDWS001 or pcDWF003 respectively [29]. HIV-1 tester viruses
were generated by co-transfecting pczVSVG with p8.91 and
pCSGW. MLV and HIV-1 were frozen in aliquots at 280uC
while EIAV and foamy viruses were freshly prepared for each
experiment.
Restriction assays
Restriction activity was routinely assayed using transient two
colour FACS analyses as described previously [19,51]. Briefly, Fv1
was introduced into MDTF cells together with an EYFP marker in
a retroviral delivery vector. Three days post-transduction, the cells
were challenged with tester viruses carrying the EGFP markers.
The cells were then subjected to FACS analyses three days later
and the percentages of tester virus positive cells in EYFP (i.e. Fv1) -
positive and - negative cells determined and compared. Ratios of
less than 0.3 were taken as restriction while those that were greater
than 0.7 were taken to represent no restriction. Numbers between
0.3 and 0.7 were taken to represent partial restriction.
Alternatively, single cell clones stably expressing restricting Fv1s
were derived by transducing MDTF cells in 12 well plates with
limiting dilutions of retroviral vectors carrying Fv1 and a G418
resistance marker. The cells from each well were transferred to a
10 cm dish and G418 was added to a concentration of 1 mg/ml.
Well-separated colonies were picked from the dishes when they
appeared 7 to 10 days after antibiotic selection was started.
Typically, 6 to 8 colonies were picked for each Fv1 cell line,
expanded and tested for restriction before being used for virus
titration. To titrate tester viruses, MDTF cells and their derivatives
were seeded in 12 well plates at a density of 56104 cells per well
24 hours prior to infection. Increasing amounts of viruses carrying
the EGFP marker were then added to the wells and the percentage
of infected cells was determined by FACS 3 days post infection.
Quantitative PCR
MDTF cells and their derivatives stably expressing Fv1 were
seeded in 6 well plates at a density of 56105 cells per well 24 hours
prior to infection. The cells were transduced at an m.o.i. of 1 with
equal amounts of viral vectors that had been pre-treated with 10
units/ml of DNase (Promega) for 1 hour at room temperature. The
cells were harvested 7 or 18 hours post-infection for quantification
of late RT products and 2 LTR circles respectively. Total genomic
DNA was extracted using the DNeasy blood and tissue kit (Qiagen)
and 250 mg or 500 mg was used for quantitative PCR to detect late
RT products and 2 LTR circles respectively. Primers and probes
directed against EGFP [67] were used for quantifying late RT
products from MLV and FFV while those directed against LacZ
were used for EIAV. The retroviral vectors fEGFPf and pHIT111
were used as standards for EGFP and LacZ quantification
respectively. Primers and probes for the detection of MLV 2 LTR
circles have been described previously [68]. In order to detect EIAV
and FFV 2 LTR circles, primers and probes that amplified and
bound to a fragment spanning the 2LTRs were designed. For EIAV
2 LTR circle detection, EIAV2LTRCF (59ACTCAGATTCTG-
CGGTCTGAG39), EIAV2LTRCRev (59ACCCCTCATAAAAA-
CCCCAC39) and EIAV2LTRCprobe (59FAM-CTCAGTCCC-
TGTCTCTAGTTTGTCTGTTCG-Tamra39) were used while
FFV2LTRCF (59CCAGAACTCACATGAGTGGTG39), FFV2
LTRCRev (59CTCATCGTCACTAGATGGCAG39) and FFV2
LTRCprobe (59FAM-GAAGGACTAACCTATCCCAGGTA-
TAGGCCG3-Tamra’) were used for the quantification of FFV
2LTR circles. The primer pairs were used to amplify fragments
spanning the 2 LTRs from genomic DNA of EIAV or FFV infected
cells. The fragments were cloned into pCR-BluntII-TOPO
(Invitrogen) to be used as standards. Quantitative PCR was
performed in 25 ml reactions using the ABsolute QPCR Rox mix
from Abgene with 300 nM of each primer and 200 nM of probe. A
programme of 50uC for 2 minutes, 95uC for 15 minutes followed by
40 cycles of 95uC for 15 s and 60uC for 1 minute was employed in
the Applied Biosystems 7500 real time PCR system.
Phylogenetic analysis
Trees were generated using the MegAlign programme from the
DNASTAR Lasergene package. The distance values were
calculated using the Kimura distance formula that takes into
account the number of non-gap mismatches and silent substitu-
tions.
Supporting Information
Figure S1 Comparison of the Fv1 sequence from different mice.
Predicted amino acid sequence encoded by the Fv1 gene from 20
different sources, compared to the Fv1b allele found in C57BL
mice. Source designations are as given in Table 1. Single letter
amino acid code; . = identical to Fv1b; - = deletion; * = stop.
(PDF)
Figure S2 Western blot analysis of Mus dunni cells transduced
with Fv1s from wild mice. MDTF cells were transduced with
retroviral vectors carrying the Fv1 gene from wild mice and the
EYFP marker such that 50% of the cells were transduced, as
determined by flow cytometry. A western blot analysis was
Evolution of the Fv1 Gene
PLOS Pathogens | www.plospathogens.org 12 March 2014 | Volume 10 | Issue 3 | e1003968
performed 3 days post transduction using 25 mg of total protein
from the cell extracts as previously described [48].
(PDF)
Table S1 Primer sequences. The sequences of the primers used
in this study are listed.
(DOCX)
Acknowledgments
We thank George Kassiotis and Robin Lovell-Badge for comments on the
manuscript as well as Francois Bonhomme, Jean-Louis Gue´net, John
Coffin and Beverley Mock for DNA samples.
Author Contributions
Conceived and designed the experiments: MWY SAE JPS. Performed the
experiments: MWY EC SAE. Analyzed the data: MWY EC SAE JPS.
Wrote the paper: MWY JPS.
References
1. Compton AA, Hirsch VM, Emerman M (2012) The host restriction factor
APOBEC3G and retroviral Vif protein coeveolve due to ongoing genetic
conflict. Cell Host and Microbe 11: 91–98.
2. Emerman M, Malik HS (2010) Paleovirology–modern consequences of ancient
viruses. PLoS Biol 8: e1000301.
3. Meyerson NR, Sawyer SL (2011) Two-stepping through time: mammals and
viruses. Trends Microbiol 19: 286–294.
4. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, et al. (2012) Human
tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein.
PLoS Pathog 8: e1003093.
5. Goff SP (2007) Retroviridae: The retroviruses and their replication. In: Knipe
DM, Griffin DE, Lamb RA, Strauss SE, Howley, Marting MA, Roizman B,
editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. Chapter
55: pp1999–2069.
6. Feschotte C, Gilbert C (2012) Endogenous viruses: insights into viral evolution
and impact on host biology. Nat Rev Genet 13: 283–296.
7. Stoye JP (2012) Studies of endogenous retroviruses reveal a continuing
evolutionary saga. Nat Rev Microbiol 10: 395–406.
8. Aswad A, Katzourakis A (2012) Paleovirlogy and virally derived immunity.
Trends in Ecology and Evolution 27: 627–36.
9. Sanz-Ramos M, Stoye JP (2013) Capsid-binding retrovirus restriction factors:
discovery, restriction specificity and implications for the development of novel
therapeutics. J Gen Virol 94: 2587–98.
10. Lilly F (1970) Fv-2: identification and location of a second gene governing the
spleen focus response to Friend leukemia virus in mice. J Natl Cancer Inst 45:
163–169.
11. Pincus T, Hartley JW, Rowe WP (1971) A major genetic locus affecting
resistance to infection with murine leukemia viruses. I. Tissue culture studies of
naturally occurring viruses. J Exp Med 133: 1219–1233.
12. Rowe WP (1972) Studies of genetic transmission of murine leukemia virus by
AKR mice. I. Crosses with Fv-1 n strains of mice. J Exp Med 136: 1272–1285.
13. Rowe WP, Hartley JW (1972) Studies of genetic transmission of murine
leukemia virus by AKR mice. II. Crosses with Fv-1 b strains of mice. J Exp Med
136: 1286–1301.
14. Kozak CA, Chakraborti A (1996) Single amino acid changes in the murine
leukemia virus capsid protein gene define the target of Fv1 resistance. Virology
225: 300–305.
15. Hopkins N, Schindler J, Hynes R (1977) Six NB-tropic leukemia viruses derived
from a B-tropic virus of BALB/c have altered p30. J Virol 21: 309–318.
16. Stevens A, Bock M, Ellis S, LeTissier P, Bishop KN, et al. (2004) Retroviral
capsid determinants of Fv1 NB- and NR-tropism. J Virol 78: 9592–9598.
17. Jolicoeur P, Rassart E (1980) Effect of Fv-1 gene product on synthesis of linear
and supercoiled viral DNA in cells infected with murine leukemia virus. J Virol
33: 183–195.
18. Best S, Le Tissier P, Towers G, Stoye JP (1996) Positional cloning of the mouse
retrovirus restriction gene Fv1. Nature 382: 826–829.
19. Yap MW, Nisole S, Lynch C, Stoye JP (2004) Trim5a protein restricts both
HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101: 10786–
10791.
20. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissler P, et al. (2004) The
cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World
monkeys. Nature 427: 848–853.
21. Stremlau M, Perron M, Lee M, Li Y, Song B, et al. (2006) Specific recognition
and accelerated uncoating of retroviral capsids by the TRIM5a restriction factor.
Proc Natl Acad Sci U S A 103: 5514–5519.
22. Hilditch L, Matadeen R, Goldstone DC, Rosenthal PB, Taylor IA, et al. (2011)
Ordered assembly of murine leukemia virus capsid protein on lipid nanotubes
directs specific binding by the restriction factor, Fv1. Proc Natl Acad Sci U S A
108: 5771–5776.
23. Yap MW, Mortuza GB, Taylor IA, Stoye JP (2007) The design of artificial
retroviral restriction factors. Virology 365: 302–314.
24. Ohkura S, Yap MW, Sheldon T, Stoye JP (2006) All three variable regions of the
TRIM5a B30.2 domain can contribute to the specificity of retrovirus restriction.
J Virol 80: 8554–8565.
25. Schaller T, Hue´ S, Towers GJ (2007) An active TRIM5 protein in rabbits
indicates a common antiviral ancestor for mammalian TRIM5 proteins. J Virol
81: 11713–11721.
26. Ylinen LMJ, Keckesova Z, Webb BLJ, Gifford RJM, Smith TPL, et al. (2006)
Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-
mediated innate immunity to retroviral infection is widespread among
mammals. J Virol 80: 7332–7338.
27. Si Z, Vandegraaff N, O’hUigin C, Song B, Yuan W, et al. (2006) Evolution of a
cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral
infection. Proc Natl Acad Sci U S A 103: 7454–7459.
28. Diehl WE, Stansell E, Kaiser SM, Emerman M, Hunter E (2008) Identification
of Post-entry Restrictions to Mason-Pfizer Monkey Virus Infection in New
World Monkey Cells. J Virol 82: 11140–11151.
29. Yap MW, Lindemann D, Stanke N, Reh J, Westphal D, et al. (2008) Restriction
of foamy viruses by primate Trim5alpha. J Virol 82: 5429–5439.
30. Mortuza GB, Goldstone DC, Pashley C, Haire LF, Palmarini M, et al. (2009)
Structure of the capsid amino-terminal domain from the betaretrovirus,
Jaagsiekte sheep retrovirus. J Mol Biol 386: 1179–1192.
31. Goldstone DC, Flower TG, Ball NJ, Sanz-Ramos M, W YM, et al. (2013) A
unique spumavirus Gag N-terminal domain with functional properties of
orthoretroviral matrix and capsid. PLoS Pathog 5: e1003376.
doi:1003310.1001371/journal.ppat.1003376.
32. Sawyer SL, Wu LI, Emerman M, Malik HS (2005) Positive selection of primate
TRIM5a identifies a critical species-specific retroviral restriction domain. Proc
Natl Acad Sci U S A 102: 102.
33. Han K, Lou DI, Sawyer SL (2011) Identification of a genomic reservoir for new
TRIM genes in primate genomes. PLoS Genet 7: e1002388.
34. Goldschmidt V, Ciuffi A, Ortiz M, Brawand D, Munoz M, et al. (2008)
Antiretroviral activity of ancestral TRIM5alpha. J Virol 82: 2089–2096.
35. Johnson WE, Sawyer SL (2009) Molecular evolution of the antiretroviral TRIM5
gene. Immunogenetics 61: 163–178.
36. Kaiser SM, Malik HS, Emerman M (2007) Restriction of an extinct retrovirus
by the human TRIM5a antiviral protein. Science 316: 1756–1758.
37. Perez-Caballero D, Soll SJ, Bieniasz PD (2008) Evidence for restriction of
ancient primate gammaretroviruses by APOBEC3 but not TRIM5a proteins.
PLoS Pathogens 4: e1000181.
38. Yap MW, Stoye JP (2013) Apparent effect of rabbit endogenous lentivirus type
K acquisition on retrovirus restriction by lagomorph Trim5as. Philos
Trans R Soc Lond B Biol Sci 368: doi: 10.1098/rstb.2012.0498.
39. Qi CF, Bonhomme F, Buckler-White A, Buckler C, Orth A, et al. (1998)
Molecular phylogeny of Fv1. Mamm Genome 9: 1049–1055.
40. Yan Y, Buckler-White A, Wollenberg K, Kozak CA (2009) Origin, antiviral
function and evidence for positive selection of the gammaretrovirus restriction
gene Fv1 in the genus Mus. Proc Natl Acad Sci U S A 106: 3259–3263.
41. Kozak CA, O’Neill RR (1987) Diverse wild mouse origins of xenotropic, mink
cell focus-forming, and two types of ecotropic proviral genes. J Virol 61: 3082–
3088.
42. Tomonaga K, Coffin JM (1999) Structures of endogenous nonecotropic murine
leukemia virus (MLV) long terminal repeats in wild mice: implication for
evolution of MLVs. J Virol 73: 4327–4340.
43. Ellis SA (2000) Evolutionary and functional studies of the mouse retrovirus
restriction gene, Fv1. PhD thesis, University of London.
44. Gue´net J-L, Bonhomme F (2003) Wild mice: an ever-increasing contribution to a
popular mammalian model. Trends in Genetics 19: 24–31.
45. Bishop KN, Mortuza GB, Howell S, Yap MW, Stoye JP, et al. (2006)
Characterization of an amino-terminal dimerization domain from retroviral
restriction factor Fv1. J Virol 80: 8225–8235.
46. Craven RC, Leure-duPree AE, R. A. Weldon J, Wills JW (1995) Genetic analysis
of the major homology region of the Rous Sarcoma Virus Gag protein. J Virol
69: 4213–4227.
47. Be´nit L, de Parseval N, Casella J-F, Callebaut I, Cordonnier A, et al. (1997)
Cloning of a new murine endogenous retrovirus, MuERV-L, with strong
similarity to the human HERV-L element and a gag coding sequence closely
related to the Fv1 restriction gene. J Virol 71: 5652–5657.
48. Bishop KN, Bock M, Towers G, Stoye JP (2001) Identification of the regions of
Fv1 necessary for MLV restriction. J Virol 75: 5182–5188.
49. Lundrigan BL, Jansa SA, Tucker PK (2002) Phylogenetic relationships in the
genus Mus, based on paterrnally, maternally and biparentally inherited
characters. Syst Biol 51: 410–431.
50. Chevret P, Jenkins P, Catzeflis F (2003) Evolutionary systematics of the Indian
mouse Mus famulus Bonhote, 1898: molecular (DNA/DNA hybridization and
Evolution of the Fv1 Gene
PLOS Pathogens | www.plospathogens.org 13 March 2014 | Volume 10 | Issue 3 | e1003968
12S rRNA sequences) and morphological evidence. Zoological Journal of the
Linnean Society 137: 385–401.
51. Bock M, Bishop KN, Towers G, Stoye JP (2000) Use of a transient assay for
studying the genetic determinants of Fv1 restriction. J Virol 74: 7422–7430.
52. Sloan RD, Wainberg MD (2011) The role of unintegrated DNA in HIV
infection. Retrovirology 8: 52.
53. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML (1996) Human
Foamy Virus replication: a pathway distinct from that of retroviruses and
hepadnaviruses. Science 271: 1579–1582.
54. Sayah DM, Sokolskaja E, Berthoux L, Luban J (2004) Cyclophilin A
retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.
Nature 430: 569–573.
55. Song B, Gold B, O’hUigin C, Javanbakht M, Li X, et al. (2005) The
B30.2(SPRY) domain of retroviral restriction factor TRIM5a exhibits lineage-
specific length and sequence variation in primates. J Virol 79: 6111–6121.
56. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD (2005)
Human tripartite motif 5a domains responsible for retrovirus restriction activity
and specificity. J Virol 79: 8969–8978.
57. Li X, Sodroski J (2008) The TRIM5{alpha} B-box 2 Domain Promotes
Cooperative Binding to the Retroviral Capsid by Mediating Higher-order Self-
association. J Virol 82: 11495–11502.
58. Best S, Le Tissier PR, Stoye JP (1997) Endogenous retroviruses and the
evolution of resistance to retroviral infection. Trends Microbiol 4: 313–318.
59. Be´nit L, Lallemand J-B, Casella J-F, Philippe H, Heidmann T (1999) ERV-L
elements: a family of endogenous retrovirus-like elements active through the
evolution of mammals. J Virol 73: 3301–3308.
60. Bamunusinghe D, Liu Q, Lu X, Oler A, Kozak CA (2013) Endogenous
gammaretrovirus acquisition in Mus musculus subspecies carrying functional
variants of the XPR1 virus receptor. J Virol 87: 9845–9855.
61. Odaka T, Ikeda H, Yoshikura H, Moriwaki K, Suzuki S (1981) Fv-4: gene
controlling resistance to NB-tropic Friend murine leukemia virus. Distribution in
wild mice, introduction into genetic background of BALB/c mice, and mapping
of chromosomes. J Natl Cancer Inst 67: 1123–1127.
62. Kozak CA (2013) Evolution of different antiviral strategies in wild mice exposed
to different gammaretroviruses. Curr Opin Virol 3: 657–63.
63. Linial ML (2000) Why aren’t foamy viruses pathogenic? Trends Micribiol 8:
284–289.
64. Choudhary A, Galvin TA, Williams DK, Beren J, Bryant MA, et al. (2013)
Influence of naturally occurring simian foamy viruses (SFVs) on SIV disease
progression in the rhesus macaque (Macaca mulatta) model. Viruses 5: 1414–
1430.
65. Lander MR, Chattopadhyay SK (1984) A Mus dunni cell line that lacks
sequences closely related to endogenous murine leukemia viruses and can be
infected by ecotropic, amphotropic, xenotropic and mink cell focus-forming
viruses. J Virol 52: 695–698.
66. Goldstone DC, Yap MW, Robertson LE, Haire LF, Taylor WR, et al. (2010)
Structural and functional analysis of prehistoric lentiviruses uncovers an ancient
molecular interface. Cell Host Microbe 8: 248–259.
67. Ikeda Y, Collins MK, Radcliffe PA, Mitrophanous KA, Takeuchi Y (2002) Gene
transduction efficiency in cells of different species by HIV and EIAV vectors.
Gene Therapy 9: 932–938.
68. Serhan F, Penaud M, Petit C, Leste-Lasserre T, Trajcevski S, et al. (2004) Early
detection of a two-long-terminal-repeat junction molecule in the cytoplasm of
recombinant murine leukemia virus-infected cells. J Virol 78: 6190–6199.
69. Labuda D, Sinnett D, Richer C, Deragon J-M, Striker G (1991) Evolution
of mouse B1 repeats: 7SL RNA folding pattern conserved. J Mol Evol 32: 405–
414.
Evolution of the Fv1 Gene
PLOS Pathogens | www.plospathogens.org 14 March 2014 | Volume 10 | Issue 3 | e1003968
